Kite Pharma
15
71M
10
1.00
1
0.33
2
- Areas of investment
Summary
Kite Pharma is the famous Corporate Investor, which was founded in 2009. The main office of represented Corporate Investor is situated in the Los Angeles. The company was established in North America in United States.
Deals in the range of 50 - 100 millions dollars are the general things for fund. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year. The top amount of exits for fund were in 2017.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Kite Pharma, startups are often financed by Nest.Bio Ventures, Viventures, Utrecht Holdings. The meaningful sponsors for the fund in investment in the same round are VI Ventures, Two River, Sequoia Capital China.
Among the most popular fund investment industries, there are Health Care, Medical. The fund has exact preference in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight HiFiBiO, Gadeta, Cell Design Labs. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
This organization was formed by Arie Belldegrun, Joshua A. Kazam.
Investments analytics
Analytics
- Total investments
- 15
- Lead investments
- 1
- Exits
- 2
- Rounds per year
- 1.00
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (13)
- Medical (7)
- Therapeutics (7)
- Pharmaceutical (6)
- Life Science (4) Show 7 more
- Investments by region
-
- United States (11)
- France (1)
- China (1)
- Netherlands (2)
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 186M
- Group Appearance index
- 0.73
- Avg. company exit year
- 2
- Avg. multiplicator
- 16.48
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ensoma | 16 May 2023 | Biotechnology, Genetics, Therapeutics | Early Stage Venture | 50M | United States, Massachusetts, Boston |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.